The Trump Administration Launches Sweeping Medicaid Fraud Crackdown
The Trump administration has initiated a comprehensive effort to address fraud, waste, and abuse in Medicaid, with the Centers for Medicare and Medicaid Services (CMS) implementing significant financial and procedural measures. These actions include deferrals of federal funds, provider revalidation requirements, and heightened scrutiny of state Medicaid Fraud Control Units (MFCUs), according to official documents and state responses.
Major Financial Actions in Minnesota and California
CMS has deferred $350 million in federal Medicaid funding for Minnesota and $1.3 billion for California, marking the largest such actions in the agency’s history. The deferrals, which pause payments for past expenditures, require states to demonstrate the “allowability” of claims. In Minnesota, a $515 million quarterly federal funding withholding was initially threatened but resolved after the state submitted a corrective action plan, according to a court filing. California’s deferral includes $1.1 billion tied to home care services, with CMS citing “significant growth” in claims relative to other states.

Both states have challenged the deferrals in court. In Minnesota, a District Court ruled the deferral “historically unprecedented” but compliant with regulations, while California alleges CMS’s estimation methods for the home care deferral were flawed. The states argue that the funding pauses threaten program stability, particularly as Medicaid budgets face historic federal cuts.
State-Specific Program Integrity Reviews
CMS has sent detailed requests to California, Florida, Maine, and New York for information on Medicaid program integrity, fraud prevention, and provider oversight. These inquiries follow concerns about “high-risk” services such as home care, behavioral health, and non-emergency medical transport. States like California and Maine have emphasized that rising service usage reflects policy choices, not fraud, and highlighted robust internal safeguards.
The agency also mandated immediate revalidation of “high-risk” Medicaid providers, requiring states to submit two-year revalidation strategies. High-risk categories include providers without National Provider Identifiers (NPIs), which CMS says are vulnerable to fraud. States like New York and Florida have pledged to accelerate revalidations, though some express concerns about resource constraints.
HHS-OIG Intensifies MFCU Scrutiny
The HHS Office of the Inspector General (HHS-OIG) is reviewing all 53 state Medicaid Fraud Control Units (MFCUs) ahead of their annual recertification. In June 2026, HHS denied Hawaii’s
Worth a look
- Respiratory Virus Levels Rising Despite Low Overall Activity
- Seoul Pharmacists Oppose Expansion of Telemedicine Drug Delivery
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)